120-Day Expedited Reviews: “Up-Front” Planning Is Key, FDA/Industry Says

Coordination of advisory panel meetings will be key to implementing 120-day expedited reviews for breakthrough devices, FDA and AdvaMed agree

More from Archive

More from Medtech Insight